| Drug Name (Proprietary name/Generic name) |
Indications Addressed Click on indication to see all drugs for that indication |
Company Click a company to see all drugs for that company |
Development Status | Notes |
| CMA-676 none / CMA-676 |
Acute Myelogenous Leukemia (AML) Leukemia |
Wyeth Pharmaceuticals Philadelphia, PA |
Phase II/III | acute
myelogenous leukemia
|
| Mylotarg Mylotarg / gemtuzumab ozogamicin |
Acute Myelogenous Leukemia (AML) |
Wyeth Pharmaceuticals Philadelphia, PA |
Phase I | 18 years and
younger
|
| Drug Name (Proprietary name/Generic name) |
Indications Addressed Click on indication to see all drugs for that indication |
Company Click a company to see all drugs for that company |
Development Status | Notes |
| Atragen¨ Atragen¨ / tretinoin |
Acute Promyeloctic Leukemia (APL) Kaposi's Sarcoma Kidney Cancer Non-Hodgkin's Lymphoma Prostate Cancer |
Antigenics New York, NY |
Phase II |
|
| Gleevec Gleevec / imatinib mesylate |
Acute Promyeloctic Leukemia (APL) Glioma |
National Cancer Institute Bethesda, MD |
Phase I/II (NCI Trial) | pediatric
|
| Drug Name (Proprietary name/Generic name) |
Indications Addressed Click on indication to see all drugs for that indication |
Company Click a company to see all drugs for that company |
Development Status | Notes |
| BPD-MA none / BPD-MA |
Bone Marrow Transplantation |
QLT Vancouver, British Columbia |
Phase I | purging of
bone marrow or peripheral blood
|
| Nuvion Nuvion / SMART anti-CD3 |
Bone Marrow Transplantation Graft v. Host Disease Psoriasis Transplant Rejection |
Protein Design Labs Fremont, CA |
Phase I/II |
|
| Drug Name (Proprietary name/Generic name) |
Indications Addressed Click on indication to see all drugs for that indication |
Company Click a company to see all drugs for that company |
Development Status | Notes |
|
tigecycline none / tigecycline |
Antibiotic-Resistant Infections |
Wyeth Pharmaceuticals Philadelphia, PA |
Phase III |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name (Proprietary name/Generic name) |
Indications Addressed Click on indication to see all drugs for that indication |
Company Click a company to see all drugs for that company |
Development Status | Notes |
| adenoviral p53
none / adenoviral p53 |
Bladder Cancer Brain Tumors Breast Cancer Liver Cancer Ovarian Cancer Prostate Cancer |
Introgen Therapeutics Austin, TX |
Phase I |
|
| buthionine
sulfoximine none / buthionine sulfoximine |
Brain Tumors Cancer/Chemotherapy-Related Conditions Melanoma |
National Cancer Institute Bethesda, MD |
Phase I (NCI Trial) | overcome
resistance to cancer drugs
|
| Cereport Cereport / RMP-7 |
Brain Cancer Brain Tumors |
Alkermes Cambridge, MA |
Phase II | 6 years- 18
years
|
| phenylbutyrate
none / phenylbutyrate |
Brain Tumors Colon Cancer Solid Tumors |
National Cancer Institute Bethesda, MD |
Phase II (NCI Trial) | pediatric
patients (brain tumors)
|
| R115777 none / R115777 |
Brain Tumors Solid Tumors |
Johnson & Johnson Pharmaceutical Research and Development Raritan, NJ |
Phase III | 2 years - 18
years
|
| SU5416 none / SU5416 |
Brain Tumors |
National Cancer Institute Bethesda, MD |
Phase I (NCI Trial) | pediatric
patients
|